Jianfeng Group was awarded the title of "Advanced Zhejiang Business Enterprise to Combat the New Crown Pneumonia Epidemic"
Release time:
2021-03-12
News Zhejiang Provincial Federation of Industry and Commerce recently issued a notice to the fight against the new coronary pneumonia epidemic to make outstanding achievements in the advanced Zhejiang business enterprises to praise, Jianfeng Group among them, was awarded the "fight against the new coronary pneumonia epidemic advanced Zhejiang business enterprises" title.
circular said that in the severe fight against the new coronary pneumonia epidemic, the vast number of Zhejiang business enterprises give full play to their own advantages, actively fulfill their social responsibilities, and actively participate in the people's war to deal with the epidemic prevention and control through various channels such as donations, donations, organization of conversion and resumption of production, global procurement of epidemic prevention materials and direct participation in the front line of anti-epidemic, which not only provides strong material support for epidemic prevention and control, it has also made important contributions to the solid work of the "six stability", the implementation of the "six protection" tasks and the promotion of economic and social development.
2020 At the beginning of the year, the new coronary pneumonia epidemic suddenly broke out on a large scale, the company paid close attention to the development trend of the epidemic, the first time to formulate and implement various epidemic prevention and control measures, strengthen the publicity of epidemic prevention and control knowledge, organize the preparation of epidemic prevention materials for Jinhua and some foreign enterprises, and strengthen the dynamic management of employee health. Jinhua City Pharmaceutical Company, peak pharmacy Spring Festival, the use of their own business channels, to help the company to do a good job of material reserves, but also for the government epidemic prevention departments to provide support. Daye Peak and Yunnan Peak Enterprises organized personnel to insist on production during the Spring Festival. After the Spring Festival holiday, in order to resume work and production as soon as possible, cadres and employees of Daye, Yunnan and Guizhou overseas enterprises overcame many difficulties and returned to their jobs. Daye Peak is at the core of the epidemic area. It insists on producing until the stock of raw coal is exhausted, and organizes limited manpower and material resources to carry out technical reform and equipment maintenance. Before and after the Lantern Festival, Daye's management team did everything possible to take risks to return to the factory. On the premise of epidemic prevention and control, Daye's management team coordinated and organized the maintenance team to enter the site and carry out the maintenance and technical transformation of the production line. Huang Ping Jianfeng actively planned the deployment and resumed the construction as soon as possible. As a result of timely prevention and control, effective measures, the Group and foreign enterprises are in the local first approval to resume production, quickly overcome the impact of the epidemic, back to normal working conditions. During the year, the project construction, market expansion, management optimization and other work of the subordinate enterprises were carried out in an orderly manner, and the work objectives set at the beginning of the year were basically completed.
In order to help the whole society fight against the epidemic, the group company and its subordinate enterprises have also donated cash and masks, protective clothing, disinfectant and other materials to the local government, charitable organizations and medical institutions, with a value of millions of yuan. Jinhua Pharmaceutical Company and Jianfeng Pharmacy not only actively organize relevant epidemic prevention materials, but also insist on affordable sales, to stabilize the market, stabilize people's hearts, and work together to "fight the epidemic" has made a positive contribution. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page